Skip to main content

Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy.

Publication ,  Journal Article
Penny, C; Nath, N; Kheterpal, M
Published in: J Drugs Dermatol
June 1, 2022

Immune checkpoint inhibitors including programmed death protein 1 inhibitors show great therapeutic benefit for numerous advanced malignancies but can cause a spectrum of immune-related adverse events, with cutaneous toxicity being a common presentation. This report includes two cases of lung adenocarcinoma treated with pembrolizumab that developed rare presentations of diffuse bullous lichenoid dermatitis involving >50% total body surface area. These cases were successfully treated in the outpatient setting with oral dexamethasone and minimal interruption of pembrolizumab therapy, a more conservative approach than current guidelines suggest. J Drugs Dermatol. 2022;21(6):668-670. doi:10.36849/JDD.6715.

Duke Scholars

Published In

J Drugs Dermatol

DOI

ISSN

1545-9616

Publication Date

June 1, 2022

Volume

21

Issue

6

Start / End Page

668 / 670

Location

United States

Related Subject Headings

  • Outpatients
  • Lung Neoplasms
  • Humans
  • Dermatitis
  • Antineoplastic Agents, Immunological
  • Antibodies, Monoclonal, Humanized
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Penny, C., Nath, N., & Kheterpal, M. (2022). Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy. J Drugs Dermatol, 21(6), 668–670. https://doi.org/10.36849/JDD.6715
Penny, Caitlin, Neel Nath, and Meenal Kheterpal. “Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy.J Drugs Dermatol 21, no. 6 (June 1, 2022): 668–70. https://doi.org/10.36849/JDD.6715.
Penny C, Nath N, Kheterpal M. Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy. J Drugs Dermatol. 2022 Jun 1;21(6):668–70.
Penny, Caitlin, et al. “Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy.J Drugs Dermatol, vol. 21, no. 6, June 2022, pp. 668–70. Pubmed, doi:10.36849/JDD.6715.
Penny C, Nath N, Kheterpal M. Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy. J Drugs Dermatol. 2022 Jun 1;21(6):668–670.

Published In

J Drugs Dermatol

DOI

ISSN

1545-9616

Publication Date

June 1, 2022

Volume

21

Issue

6

Start / End Page

668 / 670

Location

United States

Related Subject Headings

  • Outpatients
  • Lung Neoplasms
  • Humans
  • Dermatitis
  • Antineoplastic Agents, Immunological
  • Antibodies, Monoclonal, Humanized